|

BI 764532, dose 1 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Obrixtamig

Pipeline

Phase 2: 1

Top Sponsors

  • Boehringer Ingelheim1

Indications

  • Extra-pulmonary Neuroendocrine Carcinoma1
  • Neuroendocrine Neoplasms1
  • Small Cell Lung Carcinoma1
  • Lung Cancer1
  • Cancer1

Mobile, Alabama1 trial

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Infirmary Cancer Care

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.